Type II of heparin-associated thrombocytopenia (HAT) is well known, but the cardinal symptom, thrombocytopenia, is rarely adequately considered. Serious and potential lethal complications such as pulmonary embolism, cerebral stroke, or limb gangrene are often falsely regarded as insufficient anticoagulation. Guided diagnosis and therapy are of vital importance for the patient's outcome. Based on the experience of patients with HAT Type II treated in the intensive care unit, a diagnostic and therapeutic approach to the cardinal symptom thrombocytopenia is presented. A recently developed heparin-induced platelet activation assay (HIPAA) seems to be a highly sensitive laboratory test. The first therapeutic principle in case of presumed and diagnosed HAT is the cessation of unfractioned or low-molecular-weight heparins. ORG 10172 (Orgaran@), a low-sulfated heparinoid with a low cross-reactivity (10%) to heparins, can be regarded as the most effective anticoagulant in patients with HAT Type II.
Get full access to this article
View all access options for this article.
References
1.
Anderson GP: Insights to heparin-induced thrombocytopenia. Br J Haematol80:504-508, 1992.
Chong BH, Magnani HN: Orgaran in heparin-induced thrombocytopenia. Haemostasis22:85-91, 1992.
4.
Greinacher A. , Michels I., Kiefel V., et al: A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemostasis66:734-736, 1991.
5.
Ortel TL, Gockerman J., Califf R., et al: Parenteral anticoagulation with the heparinoid Lomoparan (ORG 10172) in patients with heparin-induced thrombocytopenia and thrombosis. Thromb Haemostasis67:292-296, 1992.
6.
Greinacher A. , Michels I., Schaefer M., et al: Heparin-associated thrombocytopenia with polysulphated chondroitine sulphate: Evidence for immunological cross-reactivity between heparin and polysulphated glycosaminoglycan. Br J Haematol81:252-254, 1992.
7.
Feng WC, Singh AK, Bert AH, et al: Perioperative paraplegia and multiorgan failure from heparin-induced thrombocytopenia. Ann Thorac Surg55:1555-1557, 1993.
8.
Chong BH, Pilgrim RL, Cooley MA, et al: Increased expression of platelet IgG- Fc-receptors in immune heparin-induced thrombocytopenia. Blood81:988-993, 1993.
9.
Warketin TE, Hayward CP, Smith CA, et al: Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med120:371-379, 1992.
10.
Greinacher A., Michels I., Mueller-Eckhardt C.: Heparin-associated thrombocytopenia: The antibody is not heparin specific. Thromb Haemostasis67:292-296, 1992.
11.
Greinacher A., Mueller-Eckhardt C.: Diagnostics of heparin-associated thrombocytopenia. Dtsch Med Wochenschr116:1479-1482, 1991.
12.
Kleinschmidt S., Seyfert UT, Wenzel E.: Heparin-associated thrombocytopenia (HAT) Type II—Still a diagnostic and therapeutical problem in clinical practice (abstract). Ann Hematol68 (supplement II):A80.
13.
Lévy G., Lévy PY, Jamet M., et al: Thrombocytopenia due to a low molecular weight heparin during treatment with hypotensive and diuretic drugs. Ann Fr Anesth Reanim10:586-588, 1991.
14.
Hopf HB, Flossdorf T., Breulmann M.: Recombinant tissue type plasminogen activator for the treatment of perioperative, life-threatening pulmonary embolism. Anaesthesist40:309-314, 1991.
15.
Chong BH, Burgess J., Ismail F.: The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost69:344-350, 1993.
16.
Chin, SP, Alvado G., Lemoine P.: Thrombocytopenia after a low molecular weight heparin. Ann Fr Anaesth Reanim11:587-591, 1991.
17.
Lecomte T., Shao KL, Stieltjes N., et al: Thrombocytopenia associated with low molecular weight heparin . Lancet338:1217, 1991.
18.
Kleinschmidt S., Ziegenfuss T., Seyfert UT, et al: Septic-toxic cardiovascular failure resulting from heparin-induced thrombocytopenia with "white-clot-syndrome."Anaesthesiol Intensivmed Notfallmed Schmerzther28:58-60, 1993.
19.
Drug Commission of German Medical Profession : Undesired side-effects after unfractioned and low molecular weight heparins. Deutsches Aerzteblatt89:B2119-2120, 1992.
20.
Meuleman DG : Orgaran (ORG 10172): Its pharmacological profile in experimental models. Haemostasis22:58-65, 1992.
21.
Matsuo T., Kario K., Chikahira Y., et al: Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor. Br J Haematol82:627-629, 1992.
22.
Kappa JR, Ellison N., Fisher CA, et al: The use of iloprost (ZK 36374) to permit cardiopulmonary bypass in 2 patients with heparin-induced thrombocytopenia. Anesthesiology63:A 85, 1985.
23.
Makhoul R., McCann R., Austin E., et al: Management of patients with heparin-associated thrombocytopenia and thrombosis requiring cardiac surgery. Ann Thorac Surg43:617-621, 1987.
24.
Vender JS, Matthew EB, Silverman IM, et al: Heparin-associated thrombocytopenia: Alternative managements . Anaesth Analg65:520-522, 1986.
25.
Bichler J., Fritz H.: Hirudin, a new therapeutic tool?Ann Haematol63:67-76, 1991.
26.
Blaesel JF, Rasko JE, Rickard KA, et al: Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome. Med J Aust156:192-193, 1992.
